Leukotriene Receptor Antagonists and Biosynthesis Inhibitors in Asthma
Summary The 5-lipoxygenase metabolites of arachidonic acid, leukotrienes B4, C4, D4 and E4, are potent pro-inflammatory mediators that are implicated in the pathophysiology of asthma. Therefore, many antileukotriene compounds have been developed. Two major categories of these drugs are presently und...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Diamant, Zuzana [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1994 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© Adis International Limited 1994 |
|---|
| Übergeordnetes Werk: |
Enthalten in: BioDrugs - Berlin [u.a.] : Springer, 1997, 2(1994), 3 vom: Sept., Seite 220-232 |
|---|---|
| Übergeordnetes Werk: |
volume:2 ; year:1994 ; number:3 ; month:09 ; pages:220-232 |
| Links: |
|---|
| DOI / URN: |
10.1007/BF03259270 |
|---|
| Katalog-ID: |
SPR03297728X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR03297728X | ||
| 003 | DE-627 | ||
| 005 | 20230519224640.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s1994 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/BF03259270 |2 doi | |
| 035 | |a (DE-627)SPR03297728X | ||
| 035 | |a (SPR)BF03259270-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Diamant, Zuzana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Leukotriene Receptor Antagonists and Biosynthesis Inhibitors in Asthma |
| 264 | 1 | |c 1994 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Adis International Limited 1994 | ||
| 520 | |a Summary The 5-lipoxygenase metabolites of arachidonic acid, leukotrienes B4, C4, D4 and E4, are potent pro-inflammatory mediators that are implicated in the pathophysiology of asthma. Therefore, many antileukotriene compounds have been developed. Two major categories of these drugs are presently under investigation in patients with asthma: (a) leukotriene D4 receptor antagonists, which block the effects of cysteinyl leukotrienes at the receptor site; (b) leukotriene biosynthesis inhibitors, which prevent the formation of both cysteinyl leukotrienes and leukotriene B4. Both categories provide clinically relevant protection against bronchoconstrictor stimuli, such as exercise, cold dry air, and aspirin (acetylsalicylic acid). Unexpectedly, in allergen inhalation studies, leukotriene receptor antagonists have been shown to be more effective than the biosynthesis inhibitors. Consequently, owing to their favourable pharmacokinetic profile, potent antileukotriene drugs represent a potential first-line treatment in the management of certain types of asthma such as exercise and aspirin-induced asthma. However, the definite place in therapy of both categories of drugs will depend on the results of long term treatment in the various subgroups of asthmatic patients in comparison with and in addition to present antiasthma medication. | ||
| 650 | 4 | |a Asthma |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Airway Smooth Muscle |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Allergy Clin Immunol |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a LTB4 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Allergen Challenge |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Lammers, Jan-Willem J. |4 aut | |
| 700 | 1 | |a Sterk, Peter J. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BioDrugs |d Berlin [u.a.] : Springer, 1997 |g 2(1994), 3 vom: Sept., Seite 220-232 |w (DE-627)327644672 |w (DE-600)2043743-2 |x 1179-190X |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:1994 |g number:3 |g month:09 |g pages:220-232 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/BF03259270 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 1994 |e 3 |c 09 |h 220-232 | ||
| author_variant |
z d zd j w j l jwj jwjl p j s pj pjs |
|---|---|
| matchkey_str |
article:1179190X:1994----::ektinrcpoatgnssnboytei |
| hierarchy_sort_str |
1994 |
| publishDate |
1994 |
| allfields |
10.1007/BF03259270 doi (DE-627)SPR03297728X (SPR)BF03259270-e DE-627 ger DE-627 rakwb eng Diamant, Zuzana verfasserin aut Leukotriene Receptor Antagonists and Biosynthesis Inhibitors in Asthma 1994 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Limited 1994 Summary The 5-lipoxygenase metabolites of arachidonic acid, leukotrienes B4, C4, D4 and E4, are potent pro-inflammatory mediators that are implicated in the pathophysiology of asthma. Therefore, many antileukotriene compounds have been developed. Two major categories of these drugs are presently under investigation in patients with asthma: (a) leukotriene D4 receptor antagonists, which block the effects of cysteinyl leukotrienes at the receptor site; (b) leukotriene biosynthesis inhibitors, which prevent the formation of both cysteinyl leukotrienes and leukotriene B4. Both categories provide clinically relevant protection against bronchoconstrictor stimuli, such as exercise, cold dry air, and aspirin (acetylsalicylic acid). Unexpectedly, in allergen inhalation studies, leukotriene receptor antagonists have been shown to be more effective than the biosynthesis inhibitors. Consequently, owing to their favourable pharmacokinetic profile, potent antileukotriene drugs represent a potential first-line treatment in the management of certain types of asthma such as exercise and aspirin-induced asthma. However, the definite place in therapy of both categories of drugs will depend on the results of long term treatment in the various subgroups of asthmatic patients in comparison with and in addition to present antiasthma medication. Asthma (dpeaa)DE-He213 Airway Smooth Muscle (dpeaa)DE-He213 Allergy Clin Immunol (dpeaa)DE-He213 LTB4 (dpeaa)DE-He213 Allergen Challenge (dpeaa)DE-He213 Lammers, Jan-Willem J. aut Sterk, Peter J. aut Enthalten in BioDrugs Berlin [u.a.] : Springer, 1997 2(1994), 3 vom: Sept., Seite 220-232 (DE-627)327644672 (DE-600)2043743-2 1179-190X nnns volume:2 year:1994 number:3 month:09 pages:220-232 https://dx.doi.org/10.1007/BF03259270 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 2 1994 3 09 220-232 |
| spelling |
10.1007/BF03259270 doi (DE-627)SPR03297728X (SPR)BF03259270-e DE-627 ger DE-627 rakwb eng Diamant, Zuzana verfasserin aut Leukotriene Receptor Antagonists and Biosynthesis Inhibitors in Asthma 1994 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Limited 1994 Summary The 5-lipoxygenase metabolites of arachidonic acid, leukotrienes B4, C4, D4 and E4, are potent pro-inflammatory mediators that are implicated in the pathophysiology of asthma. Therefore, many antileukotriene compounds have been developed. Two major categories of these drugs are presently under investigation in patients with asthma: (a) leukotriene D4 receptor antagonists, which block the effects of cysteinyl leukotrienes at the receptor site; (b) leukotriene biosynthesis inhibitors, which prevent the formation of both cysteinyl leukotrienes and leukotriene B4. Both categories provide clinically relevant protection against bronchoconstrictor stimuli, such as exercise, cold dry air, and aspirin (acetylsalicylic acid). Unexpectedly, in allergen inhalation studies, leukotriene receptor antagonists have been shown to be more effective than the biosynthesis inhibitors. Consequently, owing to their favourable pharmacokinetic profile, potent antileukotriene drugs represent a potential first-line treatment in the management of certain types of asthma such as exercise and aspirin-induced asthma. However, the definite place in therapy of both categories of drugs will depend on the results of long term treatment in the various subgroups of asthmatic patients in comparison with and in addition to present antiasthma medication. Asthma (dpeaa)DE-He213 Airway Smooth Muscle (dpeaa)DE-He213 Allergy Clin Immunol (dpeaa)DE-He213 LTB4 (dpeaa)DE-He213 Allergen Challenge (dpeaa)DE-He213 Lammers, Jan-Willem J. aut Sterk, Peter J. aut Enthalten in BioDrugs Berlin [u.a.] : Springer, 1997 2(1994), 3 vom: Sept., Seite 220-232 (DE-627)327644672 (DE-600)2043743-2 1179-190X nnns volume:2 year:1994 number:3 month:09 pages:220-232 https://dx.doi.org/10.1007/BF03259270 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 2 1994 3 09 220-232 |
| allfields_unstemmed |
10.1007/BF03259270 doi (DE-627)SPR03297728X (SPR)BF03259270-e DE-627 ger DE-627 rakwb eng Diamant, Zuzana verfasserin aut Leukotriene Receptor Antagonists and Biosynthesis Inhibitors in Asthma 1994 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Limited 1994 Summary The 5-lipoxygenase metabolites of arachidonic acid, leukotrienes B4, C4, D4 and E4, are potent pro-inflammatory mediators that are implicated in the pathophysiology of asthma. Therefore, many antileukotriene compounds have been developed. Two major categories of these drugs are presently under investigation in patients with asthma: (a) leukotriene D4 receptor antagonists, which block the effects of cysteinyl leukotrienes at the receptor site; (b) leukotriene biosynthesis inhibitors, which prevent the formation of both cysteinyl leukotrienes and leukotriene B4. Both categories provide clinically relevant protection against bronchoconstrictor stimuli, such as exercise, cold dry air, and aspirin (acetylsalicylic acid). Unexpectedly, in allergen inhalation studies, leukotriene receptor antagonists have been shown to be more effective than the biosynthesis inhibitors. Consequently, owing to their favourable pharmacokinetic profile, potent antileukotriene drugs represent a potential first-line treatment in the management of certain types of asthma such as exercise and aspirin-induced asthma. However, the definite place in therapy of both categories of drugs will depend on the results of long term treatment in the various subgroups of asthmatic patients in comparison with and in addition to present antiasthma medication. Asthma (dpeaa)DE-He213 Airway Smooth Muscle (dpeaa)DE-He213 Allergy Clin Immunol (dpeaa)DE-He213 LTB4 (dpeaa)DE-He213 Allergen Challenge (dpeaa)DE-He213 Lammers, Jan-Willem J. aut Sterk, Peter J. aut Enthalten in BioDrugs Berlin [u.a.] : Springer, 1997 2(1994), 3 vom: Sept., Seite 220-232 (DE-627)327644672 (DE-600)2043743-2 1179-190X nnns volume:2 year:1994 number:3 month:09 pages:220-232 https://dx.doi.org/10.1007/BF03259270 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 2 1994 3 09 220-232 |
| allfieldsGer |
10.1007/BF03259270 doi (DE-627)SPR03297728X (SPR)BF03259270-e DE-627 ger DE-627 rakwb eng Diamant, Zuzana verfasserin aut Leukotriene Receptor Antagonists and Biosynthesis Inhibitors in Asthma 1994 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Limited 1994 Summary The 5-lipoxygenase metabolites of arachidonic acid, leukotrienes B4, C4, D4 and E4, are potent pro-inflammatory mediators that are implicated in the pathophysiology of asthma. Therefore, many antileukotriene compounds have been developed. Two major categories of these drugs are presently under investigation in patients with asthma: (a) leukotriene D4 receptor antagonists, which block the effects of cysteinyl leukotrienes at the receptor site; (b) leukotriene biosynthesis inhibitors, which prevent the formation of both cysteinyl leukotrienes and leukotriene B4. Both categories provide clinically relevant protection against bronchoconstrictor stimuli, such as exercise, cold dry air, and aspirin (acetylsalicylic acid). Unexpectedly, in allergen inhalation studies, leukotriene receptor antagonists have been shown to be more effective than the biosynthesis inhibitors. Consequently, owing to their favourable pharmacokinetic profile, potent antileukotriene drugs represent a potential first-line treatment in the management of certain types of asthma such as exercise and aspirin-induced asthma. However, the definite place in therapy of both categories of drugs will depend on the results of long term treatment in the various subgroups of asthmatic patients in comparison with and in addition to present antiasthma medication. Asthma (dpeaa)DE-He213 Airway Smooth Muscle (dpeaa)DE-He213 Allergy Clin Immunol (dpeaa)DE-He213 LTB4 (dpeaa)DE-He213 Allergen Challenge (dpeaa)DE-He213 Lammers, Jan-Willem J. aut Sterk, Peter J. aut Enthalten in BioDrugs Berlin [u.a.] : Springer, 1997 2(1994), 3 vom: Sept., Seite 220-232 (DE-627)327644672 (DE-600)2043743-2 1179-190X nnns volume:2 year:1994 number:3 month:09 pages:220-232 https://dx.doi.org/10.1007/BF03259270 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 2 1994 3 09 220-232 |
| allfieldsSound |
10.1007/BF03259270 doi (DE-627)SPR03297728X (SPR)BF03259270-e DE-627 ger DE-627 rakwb eng Diamant, Zuzana verfasserin aut Leukotriene Receptor Antagonists and Biosynthesis Inhibitors in Asthma 1994 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Limited 1994 Summary The 5-lipoxygenase metabolites of arachidonic acid, leukotrienes B4, C4, D4 and E4, are potent pro-inflammatory mediators that are implicated in the pathophysiology of asthma. Therefore, many antileukotriene compounds have been developed. Two major categories of these drugs are presently under investigation in patients with asthma: (a) leukotriene D4 receptor antagonists, which block the effects of cysteinyl leukotrienes at the receptor site; (b) leukotriene biosynthesis inhibitors, which prevent the formation of both cysteinyl leukotrienes and leukotriene B4. Both categories provide clinically relevant protection against bronchoconstrictor stimuli, such as exercise, cold dry air, and aspirin (acetylsalicylic acid). Unexpectedly, in allergen inhalation studies, leukotriene receptor antagonists have been shown to be more effective than the biosynthesis inhibitors. Consequently, owing to their favourable pharmacokinetic profile, potent antileukotriene drugs represent a potential first-line treatment in the management of certain types of asthma such as exercise and aspirin-induced asthma. However, the definite place in therapy of both categories of drugs will depend on the results of long term treatment in the various subgroups of asthmatic patients in comparison with and in addition to present antiasthma medication. Asthma (dpeaa)DE-He213 Airway Smooth Muscle (dpeaa)DE-He213 Allergy Clin Immunol (dpeaa)DE-He213 LTB4 (dpeaa)DE-He213 Allergen Challenge (dpeaa)DE-He213 Lammers, Jan-Willem J. aut Sterk, Peter J. aut Enthalten in BioDrugs Berlin [u.a.] : Springer, 1997 2(1994), 3 vom: Sept., Seite 220-232 (DE-627)327644672 (DE-600)2043743-2 1179-190X nnns volume:2 year:1994 number:3 month:09 pages:220-232 https://dx.doi.org/10.1007/BF03259270 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 2 1994 3 09 220-232 |
| language |
English |
| source |
Enthalten in BioDrugs 2(1994), 3 vom: Sept., Seite 220-232 volume:2 year:1994 number:3 month:09 pages:220-232 |
| sourceStr |
Enthalten in BioDrugs 2(1994), 3 vom: Sept., Seite 220-232 volume:2 year:1994 number:3 month:09 pages:220-232 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Asthma Airway Smooth Muscle Allergy Clin Immunol LTB4 Allergen Challenge |
| isfreeaccess_bool |
false |
| container_title |
BioDrugs |
| authorswithroles_txt_mv |
Diamant, Zuzana @@aut@@ Lammers, Jan-Willem J. @@aut@@ Sterk, Peter J. @@aut@@ |
| publishDateDaySort_date |
1994-09-01T00:00:00Z |
| hierarchy_top_id |
327644672 |
| id |
SPR03297728X |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR03297728X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519224640.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1994 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/BF03259270</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR03297728X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)BF03259270-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Diamant, Zuzana</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Leukotriene Receptor Antagonists and Biosynthesis Inhibitors in Asthma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1994</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis International Limited 1994</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary The 5-lipoxygenase metabolites of arachidonic acid, leukotrienes B4, C4, D4 and E4, are potent pro-inflammatory mediators that are implicated in the pathophysiology of asthma. Therefore, many antileukotriene compounds have been developed. Two major categories of these drugs are presently under investigation in patients with asthma: (a) leukotriene D4 receptor antagonists, which block the effects of cysteinyl leukotrienes at the receptor site; (b) leukotriene biosynthesis inhibitors, which prevent the formation of both cysteinyl leukotrienes and leukotriene B4. Both categories provide clinically relevant protection against bronchoconstrictor stimuli, such as exercise, cold dry air, and aspirin (acetylsalicylic acid). Unexpectedly, in allergen inhalation studies, leukotriene receptor antagonists have been shown to be more effective than the biosynthesis inhibitors. Consequently, owing to their favourable pharmacokinetic profile, potent antileukotriene drugs represent a potential first-line treatment in the management of certain types of asthma such as exercise and aspirin-induced asthma. However, the definite place in therapy of both categories of drugs will depend on the results of long term treatment in the various subgroups of asthmatic patients in comparison with and in addition to present antiasthma medication.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Asthma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Airway Smooth Muscle</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Allergy Clin Immunol</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">LTB4</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Allergen Challenge</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lammers, Jan-Willem J.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sterk, Peter J.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">BioDrugs</subfield><subfield code="d">Berlin [u.a.] : Springer, 1997</subfield><subfield code="g">2(1994), 3 vom: Sept., Seite 220-232</subfield><subfield code="w">(DE-627)327644672</subfield><subfield code="w">(DE-600)2043743-2</subfield><subfield code="x">1179-190X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:1994</subfield><subfield code="g">number:3</subfield><subfield code="g">month:09</subfield><subfield code="g">pages:220-232</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/BF03259270</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">1994</subfield><subfield code="e">3</subfield><subfield code="c">09</subfield><subfield code="h">220-232</subfield></datafield></record></collection>
|
| author |
Diamant, Zuzana |
| spellingShingle |
Diamant, Zuzana misc Asthma misc Airway Smooth Muscle misc Allergy Clin Immunol misc LTB4 misc Allergen Challenge Leukotriene Receptor Antagonists and Biosynthesis Inhibitors in Asthma |
| authorStr |
Diamant, Zuzana |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)327644672 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1179-190X |
| topic_title |
Leukotriene Receptor Antagonists and Biosynthesis Inhibitors in Asthma Asthma (dpeaa)DE-He213 Airway Smooth Muscle (dpeaa)DE-He213 Allergy Clin Immunol (dpeaa)DE-He213 LTB4 (dpeaa)DE-He213 Allergen Challenge (dpeaa)DE-He213 |
| topic |
misc Asthma misc Airway Smooth Muscle misc Allergy Clin Immunol misc LTB4 misc Allergen Challenge |
| topic_unstemmed |
misc Asthma misc Airway Smooth Muscle misc Allergy Clin Immunol misc LTB4 misc Allergen Challenge |
| topic_browse |
misc Asthma misc Airway Smooth Muscle misc Allergy Clin Immunol misc LTB4 misc Allergen Challenge |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
BioDrugs |
| hierarchy_parent_id |
327644672 |
| hierarchy_top_title |
BioDrugs |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)327644672 (DE-600)2043743-2 |
| title |
Leukotriene Receptor Antagonists and Biosynthesis Inhibitors in Asthma |
| ctrlnum |
(DE-627)SPR03297728X (SPR)BF03259270-e |
| title_full |
Leukotriene Receptor Antagonists and Biosynthesis Inhibitors in Asthma |
| author_sort |
Diamant, Zuzana |
| journal |
BioDrugs |
| journalStr |
BioDrugs |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1994 |
| contenttype_str_mv |
txt |
| container_start_page |
220 |
| author_browse |
Diamant, Zuzana Lammers, Jan-Willem J. Sterk, Peter J. |
| container_volume |
2 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Diamant, Zuzana |
| doi_str_mv |
10.1007/BF03259270 |
| title_sort |
leukotriene receptor antagonists and biosynthesis inhibitors in asthma |
| title_auth |
Leukotriene Receptor Antagonists and Biosynthesis Inhibitors in Asthma |
| abstract |
Summary The 5-lipoxygenase metabolites of arachidonic acid, leukotrienes B4, C4, D4 and E4, are potent pro-inflammatory mediators that are implicated in the pathophysiology of asthma. Therefore, many antileukotriene compounds have been developed. Two major categories of these drugs are presently under investigation in patients with asthma: (a) leukotriene D4 receptor antagonists, which block the effects of cysteinyl leukotrienes at the receptor site; (b) leukotriene biosynthesis inhibitors, which prevent the formation of both cysteinyl leukotrienes and leukotriene B4. Both categories provide clinically relevant protection against bronchoconstrictor stimuli, such as exercise, cold dry air, and aspirin (acetylsalicylic acid). Unexpectedly, in allergen inhalation studies, leukotriene receptor antagonists have been shown to be more effective than the biosynthesis inhibitors. Consequently, owing to their favourable pharmacokinetic profile, potent antileukotriene drugs represent a potential first-line treatment in the management of certain types of asthma such as exercise and aspirin-induced asthma. However, the definite place in therapy of both categories of drugs will depend on the results of long term treatment in the various subgroups of asthmatic patients in comparison with and in addition to present antiasthma medication. © Adis International Limited 1994 |
| abstractGer |
Summary The 5-lipoxygenase metabolites of arachidonic acid, leukotrienes B4, C4, D4 and E4, are potent pro-inflammatory mediators that are implicated in the pathophysiology of asthma. Therefore, many antileukotriene compounds have been developed. Two major categories of these drugs are presently under investigation in patients with asthma: (a) leukotriene D4 receptor antagonists, which block the effects of cysteinyl leukotrienes at the receptor site; (b) leukotriene biosynthesis inhibitors, which prevent the formation of both cysteinyl leukotrienes and leukotriene B4. Both categories provide clinically relevant protection against bronchoconstrictor stimuli, such as exercise, cold dry air, and aspirin (acetylsalicylic acid). Unexpectedly, in allergen inhalation studies, leukotriene receptor antagonists have been shown to be more effective than the biosynthesis inhibitors. Consequently, owing to their favourable pharmacokinetic profile, potent antileukotriene drugs represent a potential first-line treatment in the management of certain types of asthma such as exercise and aspirin-induced asthma. However, the definite place in therapy of both categories of drugs will depend on the results of long term treatment in the various subgroups of asthmatic patients in comparison with and in addition to present antiasthma medication. © Adis International Limited 1994 |
| abstract_unstemmed |
Summary The 5-lipoxygenase metabolites of arachidonic acid, leukotrienes B4, C4, D4 and E4, are potent pro-inflammatory mediators that are implicated in the pathophysiology of asthma. Therefore, many antileukotriene compounds have been developed. Two major categories of these drugs are presently under investigation in patients with asthma: (a) leukotriene D4 receptor antagonists, which block the effects of cysteinyl leukotrienes at the receptor site; (b) leukotriene biosynthesis inhibitors, which prevent the formation of both cysteinyl leukotrienes and leukotriene B4. Both categories provide clinically relevant protection against bronchoconstrictor stimuli, such as exercise, cold dry air, and aspirin (acetylsalicylic acid). Unexpectedly, in allergen inhalation studies, leukotriene receptor antagonists have been shown to be more effective than the biosynthesis inhibitors. Consequently, owing to their favourable pharmacokinetic profile, potent antileukotriene drugs represent a potential first-line treatment in the management of certain types of asthma such as exercise and aspirin-induced asthma. However, the definite place in therapy of both categories of drugs will depend on the results of long term treatment in the various subgroups of asthmatic patients in comparison with and in addition to present antiasthma medication. © Adis International Limited 1994 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA |
| container_issue |
3 |
| title_short |
Leukotriene Receptor Antagonists and Biosynthesis Inhibitors in Asthma |
| url |
https://dx.doi.org/10.1007/BF03259270 |
| remote_bool |
true |
| author2 |
Lammers, Jan-Willem J. Sterk, Peter J. |
| author2Str |
Lammers, Jan-Willem J. Sterk, Peter J. |
| ppnlink |
327644672 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/BF03259270 |
| up_date |
2024-07-03T15:49:54.711Z |
| _version_ |
1803573573418221568 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR03297728X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519224640.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1994 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/BF03259270</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR03297728X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)BF03259270-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Diamant, Zuzana</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Leukotriene Receptor Antagonists and Biosynthesis Inhibitors in Asthma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1994</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis International Limited 1994</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary The 5-lipoxygenase metabolites of arachidonic acid, leukotrienes B4, C4, D4 and E4, are potent pro-inflammatory mediators that are implicated in the pathophysiology of asthma. Therefore, many antileukotriene compounds have been developed. Two major categories of these drugs are presently under investigation in patients with asthma: (a) leukotriene D4 receptor antagonists, which block the effects of cysteinyl leukotrienes at the receptor site; (b) leukotriene biosynthesis inhibitors, which prevent the formation of both cysteinyl leukotrienes and leukotriene B4. Both categories provide clinically relevant protection against bronchoconstrictor stimuli, such as exercise, cold dry air, and aspirin (acetylsalicylic acid). Unexpectedly, in allergen inhalation studies, leukotriene receptor antagonists have been shown to be more effective than the biosynthesis inhibitors. Consequently, owing to their favourable pharmacokinetic profile, potent antileukotriene drugs represent a potential first-line treatment in the management of certain types of asthma such as exercise and aspirin-induced asthma. However, the definite place in therapy of both categories of drugs will depend on the results of long term treatment in the various subgroups of asthmatic patients in comparison with and in addition to present antiasthma medication.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Asthma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Airway Smooth Muscle</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Allergy Clin Immunol</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">LTB4</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Allergen Challenge</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lammers, Jan-Willem J.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sterk, Peter J.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">BioDrugs</subfield><subfield code="d">Berlin [u.a.] : Springer, 1997</subfield><subfield code="g">2(1994), 3 vom: Sept., Seite 220-232</subfield><subfield code="w">(DE-627)327644672</subfield><subfield code="w">(DE-600)2043743-2</subfield><subfield code="x">1179-190X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:1994</subfield><subfield code="g">number:3</subfield><subfield code="g">month:09</subfield><subfield code="g">pages:220-232</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/BF03259270</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">1994</subfield><subfield code="e">3</subfield><subfield code="c">09</subfield><subfield code="h">220-232</subfield></datafield></record></collection>
|
| score |
7.402439 |